Latest Coagulation Stories
CSL Behring Continues Improving Patient Well-Being; Key Milestone Achieved in PROLONG-9FP, Company's Recombinant Factor IX Fusion Protein Development Program KING OF PRUSSIA,
Leading gene therapy Company will partner with established market leader to develop a potential new treatment paradigm for hemophilia B PHILADELPHIA, Dec.
Healthcare Professionals and Patient Self-Testers Should Not Use the INRatio® and INRatio®2 PT/INR Monitor System with Certain Medical Conditions WALTHAM, Mass., Dec.
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin CARLSBAD, Calif., Dec. 7, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
SAN FRANCISCO, December 7, 2014 /PRNewswire/ -- Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest
Designation Helps Improve Patient Access to Kcentra in the Inpatient Hospital Setting KING OF PRUSSIA, Pa., Dec.
PLAINSBORO, N.J., Dec.
DIEPENBEEK, Belgium, November 25, 2014 /PRNewswire/ -- Treatment for haemophilia A patients developing Factor VIII inhibitors Apitope, the drug discovery
Just Released Results from Innovaacom Program Show 94% of Physicians More Confident Treating and Communicating Best Practices for Hemophilia Atlanta, Georgia
-Direct Oral Anticoagulant Measurement, Automated on ACL TOP® Family of Hemostasis Testing Systems- BEDFORD, Mass., Sept.
- A transitional zone between two communities containing the characteristic species of each.